London · Delayed Price · Currency is GBP · Price in GBX ValiRx Company Description
ValiRx plc, a biopharmaceutical company, engages in the development of oncology therapeutics and companion diagnostics in the United Kingdom.
The company develops VAL201, a short peptide that has completed Phase I/II trials for the treatment of prostate cancer; and VAL401, a reformulation of anti-psychotic drug risperidone, which has completed Phase II clinical trial for the treatment of end-stage non-small cell lung cancer.
It also develops VAL301, a peptide ingredient that in pre-clinical development for the treatment of endometriosis; BC201, a combination of the peptide ingredient of VAL201/VAL301 with complementary active components for the treatment for patients suffering severe symptoms of Covid-19; and CLX001, a peptide nanoparticle formulation that is in pre-clinical trial for destruction of cancer cells.
It has an agreement with University of Dundee. ValiRx plc was incorporated in 2000 and is based in England, the United Kingdom.
| Country | United Kingdom |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 14 |
| CEO | Mark Eccleston |
Contact Details
Address: Stonebridge House England, CM22 7BD United Kingdom | |
| Website | valirx.com |
Stock Details
| Ticker Symbol | VAL |
| Exchange | London Stock Exchange AIM |
| Fiscal Year | January - December |
| Reporting Currency | GBP |
| ISIN Number | GB00BLH13C52 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Mark Eccleston | Chief Executive Officer |
| James Desler | Chief Financial Officer |
| Kumar Nawani | Chief Operating Officer |